Figure. Mutation Testing Results Predict Response to Anti-EGFR Immunotherapy in Patients with Metastatic Colorectal Cancer

Candidate for Cetuximab or Panitumumab

Colorectal Cancer Mutation Panel

- Mutations not detected: Response to anti-EGFR immunotherapy more likely
- ≥1 mutation(s) detected: Response to anti-EGFR immunotherapy unlikely

Adapted from references 2-5 and 8.